跳至主要内容
临床试验/EUCTR2012-003205-10-GB
EUCTR2012-003205-10-GB进行中(未招募)1 期

A randomised placebo controlled trial of follow on Rifaximin for the prevention of relapse of Clostridium difficile associated diarrhoea. - RAPID

niversity of Nottingham0 个研究点目标入组 151 人开始时间: 2012年8月31日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
151

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • -Men/Women aged 16+ years -Successful treatment of clinically diagnosed CDAD using standard therapy (metronidazole or vancomycin given according to standard local hospital guidelines and course completed within the last 5 days). -Successful treatment of CDAD using standard therapy (metronidazole or vancomycin)given according to standard local hospital guidelines. -Able to stop chronic antibiotic use -Women of child bearing potential willing and able to use at least one highly effective contraceptive method throughout the study. In the context of this study, an effective method is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly such as: implants, injectables, combined oral contraceptives, sexual abstinence or vasectomised partner.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 10
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 55
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 115

排除标准

  • -Pregnant or breast feeding

研究者

发起方
niversity of Nottingham

相似试验

Rifaximin in the prevention of Clostridium Difficile... | 临床试验